{"id":474385,"date":"2020-03-17T10:16:01","date_gmt":"2020-03-17T10:16:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=474385"},"modified":"2020-03-17T10:16:01","modified_gmt":"2020-03-17T10:16:01","slug":"hunter-syndrome-market-insight-market-size-epidemiology-leading-companies-emerging-and-marketed-therapies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hunter-syndrome-market-insight-market-size-epidemiology-leading-companies-emerging-and-marketed-therapies-by-delveinsight_474385.html","title":{"rendered":"Hunter Syndrome Market Insight, Market Size, Epidemiology, Leading Companies, Emerging and Marketed Therapies By DelveInsight"},"content":{"rendered":"
\"Hunter<\/a><\/p>\n
\n
Hunter Syndrome Market Insight Report<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cHunter Syndrome Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the Hunter Syndrome, historical and forecasted epidemiology as well as the Hunter Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on <\/strong>Hunter Syndrome Market Insights, Epidemiology and Market Forecast-2030  <\/strong><\/p>\n

The Hunter Syndrome market<\/a> report provides current treatment practices, emerging drugs, Hunter Syndrome market share of the individual therapies, current and forecasted Hunter Syndrome <\/strong>Pain market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Hunter Syndrome treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n

 <\/p>\n

Key benefits of the report
<\/strong>1. Hunter Syndrome market report covers a descriptive overview and comprehensive insight of the Hunter Syndrome epidemiology and Hunter Syndrome market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.) 
2. Hunter Syndrome market report provides insights on the current and emerging therapies.
3. Hunter Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.  
4. Hunter Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hunter Syndrome market.<\/p>\n

“Hunter syndrome occurs almost exclusively in males”<\/p>\n

Hunter Syndrome, also known as Mucopolysaccharidosis type II (MPS II), I2S deficiency and Iduronate 2-sulfatase deficiency. It is an inherited disorder of carbohydrate metabolism that occurs almost exclusively in males. MPS II is caused by mutations in the IDS gene and is inherited in an X-linked manner. Females are generally unaffected carriers of this condition. As per National MPS Society, Hunter syndrome takes its name from Charles Hunter, the professor of medicine in Manitoba, Canada, who first described two brothers with the disease in 1917. MPS II has a wide range of symptoms that vary in severity and can be managed and treated with enzyme replacement therapies. There is no cure for MPS II and it affects 1 in 100,000 to 1 in 170,000 primarily males. It is characterized by distinctive facial features, a large head, hydrocephalus, enlargement of the liver and spleen (hepatosplenomegaly), umbilical or inguinal hernia, and hearing loss. Individuals with this condition may additionally have joint deformities and heart abnormalities involving the valves. <\/strong><\/p>\n

Request for sample pages here -> https:\/\/www.delveinsight.com\/sample-request\/hunter-syndrome-market<\/a><\/p>\n

Drugs covered<\/strong><\/p>\n

    \n
  1. 1.           <\/strong>JR-141<\/strong><\/li>\n
  2. 2.           <\/strong>GC1111B or Hunterase<\/strong><\/li>\n
  3. 3.          <\/strong>RGX-121<\/strong><\/li>\n<\/ol>\n

    And many others<\/p>\n

    The key players in Hunter Syndrome <\/strong>market are:<\/strong><\/p>\n

      \n
    1. JCR Pharmaceuticals<\/strong><\/li>\n
    2. Green Cross Corporation<\/strong><\/li>\n
    3. Regenxbio Inc.<\/strong><\/li>\n<\/ol>\n

      And many others<\/p>\n

      Table of contents<\/strong><\/p>\n

      1. Report Introduction<\/strong><\/p>\n

      2. Hunter Syndrome Market Overview at a Glance<\/strong><\/p>\n

      3. Hunter syndrome Disease Background and Overview<\/strong><\/p>\n

      4. Hunter syndrome Epidemiology and Patient Population<\/strong><\/p>\n

      5. Epidemiology of Hunter syndrome by Countries (2017–2030)<\/strong><\/p>\n

      5.1. United States- Epidemiology (2017–2030)<\/strong><\/p>\n

      5.2. EU-5 – Epidemiology (2017–2030)<\/strong><\/p>\n

      5.3. Germany-Epidemiology (2017–2030)<\/strong><\/p>\n

      5.4. France-Epidemiology (2017–2030)<\/strong><\/p>\n

      5.5. Italy-Epidemiology (2017–2030)<\/strong><\/p>\n

       5.6. Spain-Epidemiology (2017–2030)<\/strong><\/p>\n

      5.7. United Kingdom-Epidemiology (2017–2030)<\/strong><\/p>\n

      5.8. Japan-Epidemiology (2017–2030)<\/strong><\/p>\n

      6. Treatments & Medical Practices<\/strong><\/p>\n

      7. Hunter syndrome Marketed Products<\/strong><\/p>\n

      7.1. Elaprase: Shire<\/strong><\/p>\n

      8. Emerging Therapies<\/strong><\/p>\n

      8.1. Key Cross Competition<\/strong><\/p>\n

      8.2. JR-141: JCR Pharmaceuticals<\/strong><\/p>\n

      8.3. GC1111B or Hunterase: Green Cross Corporation<\/strong><\/p>\n

      8.4. RGX-121: Regenxbio Inc.<\/strong><\/p>\n

      9. Hunter syndrome Market Size<\/strong><\/p>\n

      10. 7MM: Country-Wise Market Analysis<\/strong><\/p>\n

      10.1. United States Market Size<\/strong><\/p>\n

      10.2. Germany Market Size<\/strong><\/p>\n

      10.3. France Market Size<\/strong><\/p>\n

       10.4. Italy Market Size<\/strong><\/p>\n

      10.5. Spain Market Size<\/strong><\/p>\n

      10.6. United Kingdom Market Size<\/strong><\/p>\n

      10.7. Japan Market Size<\/strong><\/p>\n

      11. Market Drivers<\/strong><\/p>\n

      12. Market Barriers<\/strong><\/p>\n

      13. Report Methodology<\/strong><\/p>\n

      14. DelveInsight Capabilities<\/strong><\/p>\n

      15. Disclaimer<\/strong><\/p>\n

      16. About DelveInsight<\/strong><\/p>\n

      Request for sample pages here ->https:\/\/www.delveinsight.com\/sample-request\/hunter-syndrome-market<\/a><\/p>\n

      Related Reports:<\/strong><\/p>\n